Cargando…

Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, and there has been a rapid increase in cases worldwide. NAFLD is rapidly becoming the leading cause of hepatocellular carcinoma and is also associated with an increased risk of cardiovascular disease or exac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoneda, Masato, Kobayashi, Takashi, Iwaki, Michihiro, Nogami, Asako, Saito, Satoru, Nakajima, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651384/ https://www.ncbi.nlm.nih.gov/pubmed/37560797 http://dx.doi.org/10.5009/gnl220545

Ejemplares similares

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Nogami, Asako, et al.
Publicado: (2023)

A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs
por: Kobayashi, Takashi, et al.
Publicado: (2022)

The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Current Research on the Pathogenesis of NAFLD/NASH and the Gut–Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome
por: Kobayashi, Takashi, et al.
Publicado: (2022)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
por: Yoneda, Masato, et al.
Publicado: (2021)

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
por: Yoneda, Masato, et al.
Publicado: (2023)

Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
por: Nagai, Koki, et al.
Publicado: (2023)

Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study
por: Iwaki, Michihiro, et al.
Publicado: (2022)

Endotoxins and Non-Alcoholic Fatty Liver Disease
por: Kessoku, Takaomi, et al.
Publicado: (2021)

Comparison of long‐term prognosis between non‐obese and obese patients with non‐alcoholic fatty liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2022)

Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study
por: Kasai, Yuki, et al.
Publicado: (2022)

Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
por: Niikura, Toshihiro, et al.
Publicado: (2020)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
por: Nakajima, Kei
Publicado: (2012)

Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods
por: Yoneda, Masato, et al.
Publicado: (2017)

Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Sumida, Yoshio, et al.
Publicado: (2020)

Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma
por: Kurokawa, Suguru, et al.
Publicado: (2022)

Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs
por: Tomeno, Wataru, et al.
Publicado: (2020)

Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease
por: Hotta, Kikuko, et al.
Publicado: (2018)

Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD
por: Nogami, Asako, et al.
Publicado: (2022)

Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
por: Yoneda, Masato, et al.
Publicado: (2008)

Gastroesophageal varices evaluation using spleen‐dedicated stiffness measurement by vibration‐controlled transient elastography
por: Nagai, Koki, et al.
Publicado: (2021)

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial
por: Yoneda, Masato, et al.
Publicado: (2021)

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
por: Ozaki, Anna, et al.
Publicado: (2019)

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease
por: Kessoku, Takaomi, et al.
Publicado: (2020)

Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents
por: Hasegawa, Sho, et al.
Publicado: (2021)

Periodontal Treatment and Usual Care for Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized Controlled Trial
por: Kamata, Yohei, et al.
Publicado: (2022)

Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease
por: Hotta, Kikuko, et al.
Publicado: (2010)

Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
por: Ogawa, Yuji, et al.
Publicado: (2018)

Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study
por: Honda, Yasushi, et al.
Publicado: (2017)

Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Honda, Yasushi, et al.
Publicado: (2020)

Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
por: Yoneda, Masato, et al.
Publicado: (2022)

Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease
por: Takahashi, Hirokazu, et al.
Publicado: (2023)

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
por: Tokushige, Katsutoshi, et al.
Publicado: (2021)

Visceral obesity and the risk of Barrett's esophagus in Japanese patients with non-alcoholic fatty liver disease
por: Akiyama, Tomoyuki, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_fs5sm6vb7mnq70llspqje7ls2b